News Medicinal Cannabis A Golden Ambition For Medical Cannabis Industry?

A Golden Ambition For Medical Cannabis Industry?

-

Advertising

CREATING standardised medicine is the gold standard for the cannabis industry but the nature of the plant makes this difficult, says a leading expert.

Dr Barbara Pacchetti, of U.K. company EMMAC Life Sciences, speaking at Cannabis Europa, described cannabis as an ‘unconventional medicine’.

“The aim is for standardised medicine, and this would be the peak of Everest. Doctors are not comfortable with anything else, but with cannabis we have the plant’s entourage effect and this leads to a lot of questions and grey areas in relation to variability.

“For pharma companies, isolates are the gold standard, but there is variability with cannabis due to the different cannabinoids, plant strains, the terpenes and the flavonoids and this means we have to do more work to understand this entourage; the genetics.”

Speaking on day one of the the conference, last year, in a debate on ‘Cannabis-Based Medicines’ she said it would initially be difficult to bridge the gap left by a lack of research, due to the prohibition of cannabis over the last 60 years.

And she added: “We are just the beginning to learn and to connect with regulators, the health authorities and this will allow us to make the right cannabis medicines available to the public.”

Dianna Gutierrez, of Spanish firm Linneo Health, agreed there was much research to be done. She said it was looking at selecting different cannabis molecules and products to target different diseases.

She added: “We have to change way we produce, grow and manufacture a medicine and we need the money; huge investment from funds to get the quality of drug we require.”

Aras Azadian, of Canadian company Avicanna, said physicians like to have 

straight-forward medicines they can rely on, and this is a challenge the cannabis industry can rise to.

“They depend on one or two, high-standard products. When prescribing, it’s a case of taking it in stages – crawl, walk, run – but patients may see things differently and want different strains and flowers, for example.

“Patients have become accustomed to having the same level of consistency in their medicines, but the variability of the cannabis plant makes this difficult to achieve. 

“Cannabis medicine needs to have the highest standards; Quality assurance, and standardisation of cannabis medicine is necessary, achievable, and the responsibility of the people in this room.”

Peter
Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest news

European Moves To Brand CBD A ‘Narcotic’ Are A Growing Threat To Industry

MOVES are underway in Brussels to the restrict the sale of CBD across Europe with questions being...

UK CBD Pioneers To More Than Double Sales To Over £6m Following Canadian Takeover

CBD brand Love Hemp has been turbo-charged following its purchase by North American investors as it looks...

Legal UK Cannabis Industry Mapped Out For First Time – And Poised For Rapid Change

SOME say it's journalists who sketch history’s initial draft but this attempt to map-out the UK’s cannabis...

CBD Firms To Get Key Opportunity To Quiz FSA On Novel Food Compliance – For Free

THE European CBD industry is being given an opportunity to quiz UK regulators over the thorny issue...

Advertising

UK Medicinal Cannabis Impasse – ‘Companies Won’t Invest In Clinical Trials; Medics Only Want Clinical Trials’

A WORLD-LEADING cannabis professor says the UK is caught in a depressing Catch-22 with companies unwilling to...

Europe’s Capital Markets Poised To Open-Up To The Cannabis Industry

THE European public markets are still a capital cocoon for cannabis with regulatory issues and the recent...

Must read

Advertising

You might also likeRELATED
Recommended to you